Treatment can include CRS‐like management via IL‐6 inhibition with tocilizumab [34], while recent studies show elevation of interferon‐gamma and IL‐1beta following CRS, which prompts the role of anakinra with or without corticosteroids [37]. The gene discussed is IL6; the disease is congenital rubella syndrome.